If you have questions, please review the AUA Principles, Policies and Procedures for Managing Conflicts of Interest or the Frequently Asked Questions document. Each disclosure begins by asking the following questions 1. To whom does this disclosure apply? □ Self □ Family □ Business Partner Signature   Date _________________________________ Please return signed form to: AUA, Publications Department, 1000 Corporate Blvd. Linthicum, MD 21090 (FAX: 410-689-3906) Title: Authors: Each author must read and sign (electronic signatures are acceptable) the statements below before manuscripts will be considered for publication in Urology

Practice. selleck products Manuscripts submitted without all signatures on all statements will be returned immediately to the authors. This form is available online at www.editorialmanager.com/ju. One author should be designated as the correspondent, Selleckchem BI 6727 and the complete address, telephone number, facsimile number and e-mail address provided. Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; AND 3) final approval of the version to be published. When a large, multicenter group has conducted the work, the group should identify as authors

only those individuals who fulfill the above requirements and accept direct responsibility for the manuscript. The corresponding author must clearly indicate the preferred citation and identify all individual authors as well as the group name. Members of the group who are not designated as authors by the corresponding author will be listed in the Acknowledgments Endonuclease at the end of the manuscript. I. Authorship Responsibility, Criteria and Contributions A. By checking the appropriate boxes below, each author certifies that □ the

manuscript represents valid and original work; The following 2 sections require only the Corresponding Author signature: IV. Ethical approval of studies. 1. By checking the appropriate boxes the corresponding author certifies that a statement(s) has been included in the manuscript documenting □ Institutional review board, ethics committee or ethical review board study approval Corresponding Author Signature Date Signed ___________________________ “
“When ADT is appropriately initiated, most patients will respond favorably with clinical and/or biochemical disease remission but they will ultimately experience disease progression from androgen sensitivity to a castration resistant status.1 Options for men with mCRPC have changed dramatically in the last decade. Before 2004 when primary ADT failed, treatments were administered solely for symptom relief. Landmark chemotherapy studies demonstrated improved survival with intravenous docetaxel for patients with mCRPC.